LabConnect and OmniScience Partner to Launch First Agentic AI Platform for Real-Time Clinical Trial Lab Data Analysis
核心洞察
LabConnect (搜索) and OmniScience (搜索) announced a strategic collaboration to deliver the industry's first AI-driven solution for real-time clinical trial lab data insights.
The partnership combines LabConnect (搜索)'s central laboratory expertise with OmniScience (搜索)'s Vivo platform to unify fragmented lab datasets and automate oversight.
Vivo-Lab transforms static lab reports into dynamic, actionable intelligence, helping teams move from reactive to proactive oversight in clinical research.
LabConnect (搜索), a leading global provider of central laboratory services, announced plans to form a strategic collaboration with OmniScience (搜索), the AI company behind Vivo, to deliver the industry's first AI-driven solution enabling sponsors to gain intelligent, real-time insights from clinical trial lab data. The partnership was announced on September 15, 2025, from Johnson City, Tennessee and Houston.
Addressing Critical Data Challenges in Clinical Trials
Clinical trial lab data is often siloed, complex, and delayed, causing slow decision-making and introducing risk. By combining LabConnect (搜索)'s expertise in central lab testing and data management with OmniScience (搜索)'s Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes.
Vivo-Lab: Transforming Laboratory Data Intelligence
Vivo is an AI-native clinical trial intelligence platform that transforms how teams interact with data across the clinical development lifecycle. Designed to unify disparate sources and deliver real-time insights, Vivo functions as a control tower equipping clinical, operational, safety, and data science teams with the clarity to act faster and more confidently.
Vivo-Lab, a specialized implementation of Vivo, brings this same intelligence to laboratory data. The platform streamlines lab workflows by surfacing critical trends, anomalies, and site-level discrepancies as they happen, helping teams move from reactive to proactive oversight in one of the most complex and variable data streams in clinical research.
Industry Leadership Perspectives
"Our mission at OmniScience (搜索) is to help trial teams see and act faster," said Angela Holmes, CEO and Co-Founder of OmniScience. "Partnering with LabConnect (搜索) extends that vision by transforming lab data into real time actionable intelligence that sponsors can trust."
Wes Wheeler, CEO of LabConnect (搜索), emphasized the transformative potential of the collaboration: "At LabConnect, we're committed to helping sponsors unlock the full potential of their lab data. By integrating OmniScience (搜索)'s transformative AI, we are shifting lab results from static reports into dynamic, actionable intelligence. Together, we're giving clinical operations teams the speed, agility, and precision they need to make smarter decisions, improve trial efficiency, and bring therapies to patients faster."
Company Backgrounds and Expertise
LabConnect (搜索) specializes in Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology (搜索), cell and gene therapies, and rare & orphan diseases (搜索). The company's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise allows drug development companies to rely on one provider for all their central laboratory service needs.
OmniScience (搜索), built by a team of PhD-trained clinical data scientists, has developed Vivo as the first agentic AI control tower purpose-built for clinical trials. The platform unifies fragmented trial data, applies intelligent automation, and delivers real-time, explainable insights that help sponsors reduce costs, shorten timelines, and increase trial success rates. The company has been recognized by programs including Johnson & Johnson's JLABS, NVIDIA (搜索) Inception, and Google Cloud (搜索) for AI.
The partnership underscores both organizations' commitment to innovation in clinical development, bringing together LabConnect (搜索)'s technology-driven laboratory operations and OmniScience (搜索)'s AI-native approach to trial intelligence to accelerate the delivery of life-changing treatments to patients.